Boehringer Ingelheim’s glucagon/GLP-1 dual agonist has driven 16.6% weight loss at Week 76 of a phase 3 study. While the ...
In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a ...
SAN ANTONIO, Nov. 25, 2025 – From metabolic villain to hero? The hormone glucagon that raises blood sugar is now getting a second look to see how it actually contributes to insulin secretion, glucose ...
Severe hypoglycemia (low blood sugar) can cause people with diabetes to have seizures or lose consciousness, which can make it impossible to treat low blood sugar by eating or drinking something ...
While wholesale costs for glucagon skyrocketed over the past decade, out-of-pocket costs haven't increased by much, researchers reported. The cost of unmixed glucagon increased 192% from 2010 to 2020 ...
New findings raise the possibility of promising therapeutic strategies for the management of hypoglycemia in type 1 diabetes patients. Study: Loss of electrical β-cell to δ-cell coupling underlies ...
People with diabetes take insulin to lower high blood sugar. However, if glucose levels plunge too low—from taking too much insulin or not eating enough sugar—people can experience hypoglycemia, which ...
Researchers at Lund University in Sweden have carried out the most detailed mapping to date of the epigenome in the cells ...
No. 10 / 2026Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results